Innovation Pharmaceuticals Inc (IPIX)

[F1ash]

Let's make this simple. Daptomycin generates One BILLION dollars a year in revenue. It take 7 IV doses to accomplish what Brilacidin does in ONE.


An APPRV just sold for $350 million. Kevetrin was very effective in the mouse models for Retinoblastoma.

The current market cap for Cellceutix is only ~ 200 million.

And then there is Prurisol and Kevetrin for ovarian cancer and a preclinical for Autism and TB etc.

Do your DD, figure the likelihood of at least partial success in the upcoming trials, discount those likely future revenues to their current value. Wait patiently for everyone else to figure it out. Much less stressful.